Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline

T. Banaschewski; D. Coghill; P. Santosh; A. Zuddas; P. Asherson; J. Buitelaar; M. Danckaerts; M. Döpfner; S.V. Faraone; A. Rothenberger; J.A. Sergeant; H.C. Steinhausen; E.J.S. Sonuga-Barke; E. Taylor

doi:10.1007/s00787-006-0549-0

Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline

T. Banaschewski, D. Coghill, P. Santosh, A. Zuddas, P. Asherson, J. Buitelaar, M. Danckaerts, M. Döpfner, S.V. Faraone, A. Rothenberger, J.A. Sergeant, H.C. Steinhausen, E.J.S. Sonuga-Barke, E. Taylor

Clinical Neuropsychology

Research output: Contribution to Journal › Article › Academic › peer-review

679 Downloads (Pure)

Abstract

A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made. © 2006 Steinkopff Verlag.

Original language	English
Pages (from-to)	476-495
Number of pages	21
Journal	European Child and Adolescent Psychiatry
Volume	15
Issue number	8
DOIs	https://doi.org/10.1007/s00787-006-0549-0
Publication status	Published - 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00787-006-0549-0

Banaschewski European Child and Adolescent Psychiatry 15(8) 2006 uFinal published version, 252 KB

http://web.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=1&hid=10&sid=fd72eca1-2dbb-4f09-b22c-9dba83b66227%40sessionmgr15

Persistent URL (handle)

Copy link address

Cite this

Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., Buitelaar, J., Danckaerts, M., Döpfner, M., Faraone, S. V., Rothenberger, A., Sergeant, J. A., Steinhausen, H. C., Sonuga-Barke, E. J. S., & Taylor, E. (2006). Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. European Child and Adolescent Psychiatry, 15(8), 476-495. https://doi.org/10.1007/s00787-006-0549-0

@article{36d0e232c09a4b2a99924990718d9eb0,

title = "Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline",

abstract = "A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made. {\textcopyright} 2006 Steinkopff Verlag.",

author = "T. Banaschewski and D. Coghill and P. Santosh and A. Zuddas and P. Asherson and J. Buitelaar and M. Danckaerts and M. D{\"o}pfner and S.V. Faraone and A. Rothenberger and J.A. Sergeant and H.C. Steinhausen and E.J.S. Sonuga-Barke and E. Taylor",

year = "2006",

doi = "10.1007/s00787-006-0549-0",

language = "English",

volume = "15",

pages = "476--495",

journal = "European Child and Adolescent Psychiatry",

issn = "1018-8827",

publisher = "D. Steinkopff-Verlag",

number = "8",

}

Banaschewski, T, Coghill, D, Santosh, P, Zuddas, A, Asherson, P, Buitelaar, J, Danckaerts, M, Döpfner, M, Faraone, SV, Rothenberger, A, Sergeant, JA, Steinhausen, HC, Sonuga-Barke, EJS & Taylor, E 2006, 'Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline', European Child and Adolescent Psychiatry, vol. 15, no. 8, pp. 476-495. https://doi.org/10.1007/s00787-006-0549-0

TY - JOUR

T1 - Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline

AU - Banaschewski, T.

AU - Coghill, D.

AU - Santosh, P.

AU - Zuddas, A.

AU - Asherson, P.

AU - Buitelaar, J.

AU - Danckaerts, M.

AU - Döpfner, M.

AU - Faraone, S.V.

AU - Rothenberger, A.

AU - Sergeant, J.A.

AU - Steinhausen, H.C.

AU - Sonuga-Barke, E.J.S.

AU - Taylor, E.

PY - 2006

Y1 - 2006

N2 - A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made. © 2006 Steinkopff Verlag.

AB - A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made. © 2006 Steinkopff Verlag.

U2 - 10.1007/s00787-006-0549-0

DO - 10.1007/s00787-006-0549-0

M3 - Article

SN - 1018-8827

VL - 15

SP - 476

EP - 495

JO - European Child and Adolescent Psychiatry

JF - European Child and Adolescent Psychiatry

IS - 8

ER -

Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline

Abstract

UN SDGs

Access to Document

Persistent URL (handle)

Fingerprint

Cite this